B2M
EstablishedB2M is a cell-surface protein used as a key prognostic marker in multiple myeloma staging.
B2M is a small protein shed by cells throughout the body; high levels often mean a higher amount of cancer cells present, especially in multiple myeloma, where it's part of the standard staging system doctors use to plan treatment.
Beta-2 microglobulin (B2M) is a small protein present on the surface of nearly all nucleated cells, released into circulation in proportion to cell turnover. It is a core prognostic marker in multiple myeloma and certain lymphomas.
Elevated B2M reflects higher tumor burden and is incorporated into the International Staging System (ISS) for multiple myeloma alongside albumin; it is also elevated in various benign conditions (kidney dysfunction, inflammation, viral infection).
Measured via serum immunoassay; a value <4 μg/mL is considered a favorable prognostic factor in myeloma, with one study showing median survival of 43 months (low B2M) versus 12 months (high B2M) in older cohorts. It is also a predictor of progression risk in asymptomatic (smoldering) myeloma.
B2M contributes directly to ISS staging, which guides risk stratification and treatment intensity decisions in multiple myeloma; newer research is examining the rate of B2M decline after treatment initiation as an added prognostic signal.
Core component of the International Staging System (ISS) for multiple myeloma.
- Bataille, R., et al. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment. PubMed.
- Xu, et al. (2024). Prognostic significance of β2-microglobulin decline index in multiple myeloma. Frontiers in Oncology.